Abstract
The discovery of a genetic signature of chemosensitivity and prognosis in oligodendroglial tumours prompted a new optimism in glioma management. After more than a decade since the initial reports, where do we stand in the current management of oligodendroglial tumours? This review focuses on the latest molecular genetics, imaging characteristics, and recent trials of treatment paradigms for these tumours.
MeSH terms
-
Antineoplastic Protocols / standards
-
Brain / pathology*
-
Brain / physiopathology
-
Brain Neoplasms / diagnosis*
-
Brain Neoplasms / genetics*
-
Brain Neoplasms / therapy
-
Combined Modality Therapy / methods
-
Combined Modality Therapy / trends
-
Diagnostic Imaging / methods
-
Diagnostic Imaging / trends
-
Genetic Predisposition to Disease / genetics*
-
Humans
-
Molecular Biology / methods
-
Molecular Biology / trends
-
Oligodendroglioma / diagnosis*
-
Oligodendroglioma / genetics*
-
Oligodendroglioma / therapy
-
Prognosis
-
Survival Rate / trends